
Krystal Biotech, Inc. – NASDAQ:KRYS
Krystal Biotech stock price today
Krystal Biotech stock price monthly change
Krystal Biotech stock price quarterly change
Krystal Biotech stock price yearly change
Krystal Biotech key metrics
Market Cap | 4.59B |
Enterprise value | 1.97B |
P/E | -15.18 |
EV/Sales | N/A |
EV/EBITDA | -15.14 |
Price/Sales | N/A |
Price/Book | 4.08 |
PEG ratio | 0.20 |
EPS | 1.96 |
Revenue | N/A |
EBITDA | -38.43M |
Income | 57.16M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeKrystal Biotech stock price history
Krystal Biotech stock forecast
Krystal Biotech financial statements
Jun 2023 | 0 | -33.21M | |
---|---|---|---|
Sep 2023 | 8.55M | 80.74M | 943.75% |
Dec 2023 | 42.14M | 8.69M | 20.63% |
Mar 2024 | 45.25M | 932K | 2.06% |
Sep 2025 | 116.01M | 33.89M | 29.22% |
---|---|---|---|
Oct 2025 | 133.39M | 47.15M | 35.35% |
Dec 2025 | 125.03M | 37.49M | 29.99% |
Mar 2026 | 97.95M | 14.74M | 15.05% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 684026000 | 30.91M | 4.52% |
---|---|---|---|
Sep 2023 | 790350000 | 34.40M | 4.35% |
Dec 2023 | 818355000 | 39.71M | 4.85% |
Mar 2024 | 853296000 | 54.05M | 6.33% |
Jun 2023 | -34.19M | -15.95M | 185.26M |
---|---|---|---|
Sep 2023 | -21.22M | 105.19M | 13.38M |
Dec 2023 | -7.23M | -10.16M | 2.61M |
Mar 2024 | 15.88M | -25.98M | 10.58M |
Krystal Biotech alternative data
Aug 2023 | 210 |
---|---|
Sep 2023 | 210 |
Oct 2023 | 210 |
Nov 2023 | 210 |
Dec 2023 | 210 |
Jan 2024 | 210 |
Feb 2024 | 210 |
Apr 2024 | 229 |
May 2024 | 229 |
Jun 2024 | 229 |
Jul 2024 | 229 |
Krystal Biotech other data
Period | Buy | Sel |
---|---|---|
Jan 2024 | 0 | 2500 |
Feb 2024 | 0 | 12200 |
Mar 2024 | 0 | 100000 |
May 2024 | 0 | 20000 |
Jun 2024 | 0 | 100000 |
Sep 2024 | 0 | 100000 |
Dec 2024 | 0 | 100000 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | KRISHNAN KRISH S director, 10 perc.. | Common Stock | 727 | $170.43 | $123,903 | ||
Sale | KRISHNAN KRISH S director, 10 perc.. | Common Stock | 620 | $171.63 | $106,408 | ||
Sale | KRISHNAN SUMA director, 10 perc.. | Common Stock | 6,302 | $163.07 | $1,027,661 | ||
Sale | KRISHNAN SUMA director, 10 perc.. | Common Stock | 8,381 | $163.91 | $1,373,755 | ||
Sale | KRISHNAN SUMA director, 10 perc.. | Common Stock | 4,909 | $164.93 | $809,646 | ||
Sale | KRISHNAN SUMA director, 10 perc.. | Common Stock | 5,942 | $163.04 | $968,807 | ||
Sale | KRISHNAN KRISH S director, 10 perc.. | Common Stock | 8,381 | $163.91 | $1,373,755 | ||
Sale | KRISHNAN SUMA director, 10 perc.. | Common Stock | 1,977 | $165.82 | $327,834 | ||
Sale | KRISHNAN SUMA director, 10 perc.. | Common Stock | 923 | $166.93 | $154,074 | ||
Sale | KRISHNAN SUMA director, 10 perc.. | Common Stock | 911 | $169.65 | $154,549 |
Patent |
---|
Application Filling date: 17 Nov 2021 Issue date: 1 Sep 2022 |
Application Filling date: 25 Sep 2019 Issue date: 23 Dec 2021 |
Application Filling date: 23 Jun 2021 Issue date: 14 Oct 2021 |
Application Filling date: 28 Jun 2019 Issue date: 26 Aug 2021 |
Application Filling date: 18 Dec 2020 Issue date: 24 Jun 2021 |
Application Filling date: 6 Nov 2020 Issue date: 25 Mar 2021 |
Application Filling date: 29 Jun 2020 Issue date: 18 Feb 2021 |
Grant Filling date: 7 Feb 2020 Issue date: 10 Nov 2020 |
Grant Filling date: 26 Apr 2019 Issue date: 29 Sep 2020 |
Application Filling date: 7 Feb 2020 Issue date: 13 Aug 2020 |
Quarter | Transcript |
---|---|
Q1 2024 6 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 26 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 6 Nov 2023 | Q3 2023 Earnings Call Transcript |
Abeona Therapeutics: pz-cel Has Massive Potential For RDEB Patients
Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher
Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy
Krystal Biotech: VYJUVEK's Blockbuster Potential In Gene Therapy For DEB
Buying The Dip In Abeona Therapeutics After The Recent Manufacturing-Related CRL
Krystal Biotech's Vyjuvek Impresses Early On, Bolsters Prospects
Krystal Biotech: FDA Approval Of Vyjuvek And Further Pipeline Enhancement
Krystal Biotech: Pioneering Rare Disease Gene Therapies
Krystal Biotech: A Promising Gene Therapy Innovator
-
What's the price of Krystal Biotech stock today?
One share of Krystal Biotech stock can currently be purchased for approximately $143.96.
-
When is Krystal Biotech's next earnings date?
Unfortunately, Krystal Biotech's (KRYS) next earnings date is currently unknown.
-
Does Krystal Biotech pay dividends?
No, Krystal Biotech does not pay dividends.
-
How much money does Krystal Biotech make?
Krystal Biotech has a market capitalization of 4.59B.
-
What is Krystal Biotech's stock symbol?
Krystal Biotech, Inc. is traded on the NASDAQ under the ticker symbol "KRYS".
-
What is Krystal Biotech's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Krystal Biotech?
Shares of Krystal Biotech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Krystal Biotech's key executives?
Krystal Biotech's management team includes the following people:
- Mr. Krish S. Krishnan Chairman, Pres & Chief Executive Officer(age: 60, pay: $752,370)
- Ms. Suma M. Krishnan Founder, Chief Operating Officer & Director(age: 60, pay: $532,270)
- Ms. Kathryn A. Romano Chief Accounting Officer(age: 44, pay: $200,870)
-
Is Krystal Biotech founder-led company?
Yes, Krystal Biotech is a company led by its founder Ms. Suma M. Krishnan.
-
How many employees does Krystal Biotech have?
As Jul 2024, Krystal Biotech employs 229 workers.
-
When Krystal Biotech went public?
Krystal Biotech, Inc. is publicly traded company for more then 7 years since IPO on 20 Sep 2017.
-
What is Krystal Biotech's official website?
The official website for Krystal Biotech is krystalbio.com.
-
Where are Krystal Biotech's headquarters?
Krystal Biotech is headquartered at 2100 Wharton Street, Pittsburgh, PA.
-
How can i contact Krystal Biotech?
Krystal Biotech's mailing address is 2100 Wharton Street, Pittsburgh, PA and company can be reached via phone at +41 25865830.
Krystal Biotech company profile:

Krystal Biotech, Inc.
krystalbio.comNASDAQ
229
Biotechnology
Healthcare
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Pittsburgh, PA 15203
CIK: 0001711279
ISIN: US5011471027
CUSIP: 501147102